Encompass Health Corp (EHC)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $13.83B
Last updated: Nov 17, 2026 at 11:05 AM ET
Encompass Health Corp (EHC) Stock Forecast
Analysts expect Encompass Health (EHC) to earn $6.28 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.48B. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 10 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 1.92, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.7% |
| Buy | 12 | 92.3% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 9.7% and revenue estimates rise 8.3%.
- Fiscal year ending Dec 31, 2026
- $6.28
- EPS consensus, revenue $6.48B
- Fiscal year ending Dec 31, 2027
- $6.89
- EPS consensus, revenue $7.02B
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $6.28 | $6.12 to $6.33 | 13 | $6.48B | $6.47B to $6.49B | 12 |
| Dec 31, 2027 | $6.89 | $6.29 to $7.11 | 13 | $7.02B | $6.98B to $7.16B | 12 |
Quarterly Estimates
The EPS consensus rises from $1.62 for the quarter ending Dec 31, 2026 to $1.70 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.62 | $1.42 to $1.74 | 14 | $1.69B | $1.49B to $1.78B | 13 |
| Mar 31, 2027 | $1.70 | $1.61 to $1.75 | 8 | $1.71B | $1.70B to $1.72B | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 21 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 10 | 0 |
| Fiscal year ending Dec 31, 2027 | 10 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 4.5% from $6.01.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $6.28 | $6.11 | $6.11 | $6.11 | $6.01 | +4.6% |
| Fiscal year ending Dec 31, 2027 | $6.89 | $6.68 | $6.68 | $6.68 | $6.54 | +5.4% |
| Quarter ending Mar 31, 2027 | $1.70 | $1.71 | $1.71 | $1.71 | $1.70 | -0.3% |
Frequently Asked Questions About EHC
What is the EHC stock forecast?
Consensus analyst estimates put Encompass Health's EPS at $6.28 for the fiscal year ending Dec 31, 2026, on revenue of $6.48B. The consensus rating from 13 analysts is Buy.
How do analysts rate EHC stock?
Of 13 analysts covering Encompass Health, 1 rates it Strong Buy, 12 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from EHC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $6.28, with estimates from $6.12 to $6.33 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $6.89, with estimates from $6.29 to $7.11 from 13 analysts.
What revenue do analysts expect from Encompass Health next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.48B, with estimates from $6.47B to $6.49B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $7.02B, with estimates from $6.98B to $7.16B.
How many analysts cover EHC?
13 analysts rate Encompass Health stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
EHC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts